<code id='A2689BD56E'></code><style id='A2689BD56E'></style>
    • <acronym id='A2689BD56E'></acronym>
      <center id='A2689BD56E'><center id='A2689BD56E'><tfoot id='A2689BD56E'></tfoot></center><abbr id='A2689BD56E'><dir id='A2689BD56E'><tfoot id='A2689BD56E'></tfoot><noframes id='A2689BD56E'>

    • <optgroup id='A2689BD56E'><strike id='A2689BD56E'><sup id='A2689BD56E'></sup></strike><code id='A2689BD56E'></code></optgroup>
        1. <b id='A2689BD56E'><label id='A2689BD56E'><select id='A2689BD56E'><dt id='A2689BD56E'><span id='A2689BD56E'></span></dt></select></label></b><u id='A2689BD56E'></u>
          <i id='A2689BD56E'><strike id='A2689BD56E'><tt id='A2689BD56E'><pre id='A2689BD56E'></pre></tt></strike></i>

          leisure time

          leisure time

          author:explore    Page View:4179
          Photo illustration with orange background of Desmond Padhi, PharmD, interim CEO, Latigo (center), with Latigo board chair Nancy Stagliano (left) and Westlake Village BioPartners founding managing director Sean Harper, M.D. (right) -- biotech coverage from STAT
          Desmond Padhi, PharmD, interim CEO, Latigo (center), with Latigo board chair Nancy Stagliano (left) and Westlake Village BioPartners founding managing director Sean Harper, M.D. (right) Illustration: Christine Kao/STAT; Courtesy: Steve Shoffner & Michael Haber

          After three years being incubated by California VC Westlake Village BioPartners, a new biotech launched Wednesday with $135 million and plans to compete with Vertex Pharmaceuticals.

          The startup is called Latigo Biotherapeutics, and it’s launching having already started a Phase 1 trial for a non-opioid pain medicine, LTG-001. The oral therapy is designed to silence pain-signaling neurons by blocking a sodium channel called NaV 1.8.

          advertisement

          Westlake had set out years ago to scout out new options for pain medicines, and found a research desert, according to founding managing director Sean Harper. But NaV 1.8 has emerged as a promising option because of its potential to be non-addictive and to lessen pain without affecting a person’s central nervous system, digestion, or heart rate, as opioids can. There were still few high-quality molecules in development that could be licensed from an academic lab or another drug company, so Westlake decided to develop its own.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          comprehensive

          DIEP, the 'gold standard' of breast reconstruction, is under threat
          DIEP, the 'gold standard' of breast reconstruction, is under threat

          AdobeIn1983,Iflewhomefromcollegetobewithmymotherasshewokeupfromamastectomy.Sheoptedoutofbreastrecons

          read more
          CEOs share strategies for surviving biotech slump
          CEOs share strategies for surviving biotech slump

          JonathanWosenforSTATCARLSBAD,Calif.—BiotechCEOsleadingcellandgenetherapycompaniesspokefranklyataconf

          read more
          New air purifier tech could be key to improving indoor air quality
          New air purifier tech could be key to improving indoor air quality

          AdobeUntiltheearly20thcentury,Americaregularlyexperiencedbrutallydestructiveurbanfires.Conflagration

          read more

          Better Therapeutics data on benefit with GLP

          APStockYou’rereadingthewebeditionofSTAT’sHealthTechnewsletter,ourguidetohowtechnologyistransformingt